Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand

John Carroll

Editor & Founder

A year ago, when Philadelphia-based Carisma Therapeutics was raising a $53 million A round to back their work on macrophages in immuno-oncology, Munich-based Wellington Partners …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk is feeling the competition from compounded GLP-1s, exec says

GSK defiant against vaccine challenges, will prioritize other growth areas

Small personalized vaccine trial sees progress in late-stage kidney cancer

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

Kura's AML drug passes key study in advanced patients, plans next steps with FDA and newly diagnosed studies

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Welling­ton Part­ners tanks up with $237M for its next life sci fund — same strat­e­gy, but with more cash on hand

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Wellington Partners tanks up with $237M for its next life sci fund — same strategy, but with more cash on hand